Sarepta Therapeutics Inc
SWB:AB3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sarepta Therapeutics Inc
SWB:AB3A
|
US |
|
A
|
Akamai Technologies Inc
SWB:AK3
|
US |
|
W
|
W R Berkley Corp
F:WR1
|
US |
|
L
|
Lithium Americas Corp
F:WUC1
|
CA |
|
W
|
Wesfarmers Ltd
SWB:WF3
|
AU |
|
D
|
Digital Realty Trust Inc
SWB:FQI
|
US |
|
O
|
Orion Oyj
F:OFK
|
FI |
|
Saipem SpA
F:SPE1
|
IT |
|
S
|
Sun Communities Inc
F:SCZ
|
US |
|
Asahi Kasei Corp
F:ASA
|
JP |
|
Compagnie Immobiliere de Belgique
LSE:0NC0
|
BE |
Wall St Price Targets
AB3A Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
AB3A is 18.41 EUR with a low forecast of 4.13 EUR and a high forecast of 32.67 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AB3A's stock price target?
Price Target
18.41
EUR
According to Wall Street analysts, the average 1-year price target for
AB3A is 18.41 EUR with a low forecast of 4.13 EUR and a high forecast of 32.67 EUR.
What is the Revenue forecast for Sarepta Therapeutics Inc?
Projected CAGR
-3%
Over the last 14 years, the compound annual growth rate for Revenue has been 32%. The projected CAGR for the next 8 years is -3%.